Information:
Fel:
ID
34325
Beskrivning
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01754974
Länk
https://clinicaltrials.gov/show/NCT01754974
Nyckelord
Versioner (1)
- 2019-01-16 2019-01-16 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
16 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Hepatitis C Virus (HCV) NCT01754974
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
chronic hepatitis c, genotype 1
boolean
ID.2
Item
hcv rna ≥100,000 iu/ml at screening
boolean
ID.3
Item
liver biopsy documenting no cirrhosis (within prior 3 years). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease
boolean
ID.4
Item
naïve to prior anti-hcv therapy
boolean
ID.5
Item
infected with hcv other than genotype 1
boolean
ID.6
Item
positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv)-1/hiv-2 antibody at screening
boolean
ID.7
Item
evidence of liver disease other than hcv
boolean
ID.8
Item
active substance abuse
boolean
ID.9
Item
use of hematologic growth factors within 90 days prior to study randomization
boolean
ID.10
Item
evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria
boolean